Imagion Biosystems Limited has released Appendix 3B — Renounceable Rights Issue. Read Appendix 3B.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance